<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ATIVAN- lorazepam tablet </strong><br>Valeant Pharmaceuticals North America LLC<br></p></div>
<h1>Ativan<span class="Sup">®</span>    CIV<br> (lorazepam) Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Ativan (lorazepam), an antianxiety agent, has the chemical formula, 7-chloro-5-(<span class="Italics">o</span>-chlorophenyl)-1,3-dihydro-3-hydroxy-2<span class="Italics">H</span>-1,4-benzodiazepin-2-one:</p>
<div class="Figure">
<img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=89057c93-8155-4040-acec-64e877bd2b4c&amp;name=ativan-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">15</span>H<span class="Sub">10</span>Cl<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">2</span>       MW: 321.16</p>
</div>
<p>It is a nearly white powder almost insoluble in water. Each Ativan (lorazepam) tablet, to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam. The inactive ingredients present are lactose monohydrate, magnesium stearate, microcrystalline cellulose, and polacrilin potassium.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Clinical"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Studies in healthy volunteers show that in single high doses Ativan (lorazepam) has a tranquilizing action on the central nervous system with no appreciable effect on the respiratory or cardiovascular systems.</p>
<p>Ativan (lorazepam) is readily absorbed with an absolute bioavailability of 90 percent. Peak concentrations in plasma occur approximately 2 hours following administration. The peak plasma level of lorazepam from a 2 mg dose is approximately 20 ng/mL.</p>
<p>The mean half-life of unconjugated lorazepam in human plasma is about 12 hours and for its major metabolite, lorazepam glucuronide, about 18 hours. At clinically relevant concentrations, lorazepam is approximately 85% bound to plasma proteins. Ativan (lorazepam) is rapidly conjugated at its 3-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable CNS activity in animals.</p>
<p>The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to six months.</p>
<p>Studies comparing young and elderly subjects have shown that advancing age does not have a significant effect on the pharmacokinetics of lorazepam. However, in one study involving single intravenous doses of 1.5 to 3 mg of Ativan Injection, mean total body clearance of lorazepam decreased by 20% in 15 elderly subjects of 60 to 84 years of age compared to that in 15 younger subjects of 19 to 38 years of age.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Ativan (lorazepam) is indicated for the management of <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorders</span> or for the short-term relief of the symptoms of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> associated with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span>. <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> or <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> associated with the stress of everyday life usually does not require treatment with an anxiolytic.</p>
<p>The effectiveness of Ativan (lorazepam) in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Ativan (lorazepam) is contraindicated in patients with<br> – <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to benzodiazepines or to any components of the formulation.<br>– acute narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Pre-existing <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may emerge or worsen during use of benzodiazepines including lorazepam. Ativan (lorazepam) is not recommended for use in patients with a primary <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
<p>Use of benzodiazepines, including lorazepam, both used alone and in combination with other CNS depressants, may lead to potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. (See <a href="#Precautions_clinically">PRECAUTIONS Clinically Significant Drug Interactions</a>) </p>
<p>Use of benzodiazepines, including lorazepam, may lead to physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>As with all patients on CNS- depressant drugs, patients receiving lorazepam should be warned not to operate dangerous machinery or motor vehicles and that their tolerance for alcohol and other CNS depressants will be diminished.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>Physical and Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">The use of benzodiazepines, including lorazepam, may lead to physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. The risk of <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> increases with higher doses and longer term use and is further increased in patients with a history of <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> or drug abuse or in patients with significant <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorders</span>. The <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> potential is reduced when lorazepam is used at the appropriate dose for short-term treatment. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving lorazepam or other psychotropic agents.</p>
<p>In general, benzodiazepines should be prescribed for short periods only (e.g., 2 to 4 weeks). Extension of the treatment period should not take place without reevaluation of the need for continued therapy. Continuous long-term use of product is not recommended. Withdrawal symptoms (e.g., rebound <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) can appear following cessation of recommended doses after as little as one week of therapy. Abrupt discontinuation of product should be avoided and a gradual dosage-tapering schedule followed after extended therapy.</p>
<p>Abrupt termination of treatment may be accompanied by withdrawal symptoms. Symptoms reported following discontinuation of benzodiazepines include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, rebound phenomena, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4233346" conceptname="Derealization">derealization</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">hyperacusis</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>/<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of extremities, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to light, noise, and physical contact/perceptual changes, involuntary movements, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>/<span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, and <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> may be more common in patients with pre-existing <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders or who are taking other drugs that lower the convulsive threshold such as antidepressants.</p>
<p>There is evidence that tolerance develops to the sedative effects of benzodiazepines.</p>
<p>Lorazepam may have abuse potential, especially in patients with a history of drug and/or <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, a possibility for <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> should be borne in mind; benzodiazepines should not be used in such patients without adequate anti-depressant therapy.</p>
<p>Lorazepam should be used with caution in patients with compromised respiratory function (e.g., <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea syndrome</span>).</p>
<p>Elderly or debilitated patients may be more susceptible to the sedative effects of lorazepam. Therefore, these patients should be monitored frequently and have their dosage adjusted carefully according to patient response; the initial dosage should not exceed 2 mg.</p>
<p>Paradoxical reactions have been occasionally reported during benzodiazepine use. Such reactions may be more likely to occur in children and the elderly. Should these occur, use of the drug should be discontinued.</p>
<p>The usual precautions for treating patients with impaired renal or hepatic function should be observed. As with all benzodiazepines, the use of lorazepam may worsen <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>; therefore, lorazepam should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> and/or <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. Dosage for patients with severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> should be adjusted carefully according to patient response; lower doses may be sufficient in such patients.</p>
<p>In patients where gastrointestinal or <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span> coexist with <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, it should be noted that lorazepam has not been shown to be of significant benefit in treating the gastrointestinal or cardiovascular component.</p>
<p>Esophageal dilation occurred in rats treated with lorazepam for more than one year at 6 mg/kg/day. The no-effect dose was 1.25 mg/kg/day (approximately 6 times the maximum human therapeutic dose of 10 mg per day). The effect was reversible only when the treatment was withdrawn within two months of first observation of the phenomenon. The clinical significance of this is unknown. However, use of lorazepam for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> and in geriatric patients requires caution, and there should be frequent monitoring for symptoms of upper G.I. disease.</p>
<p>Safety and effectiveness of Ativan (lorazepam) in children of less than 12 years have not been established.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">To assure the safe and effective use of Ativan (lorazepam), patients should be informed that, since benzodiazepines may produce psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.2"></a><p></p>
<h2>Essential Laboratory Tests</h2>
<p class="First">Some patients on Ativan (lorazepam) have developed <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver-function tests are recommended for patients on long-term therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Precautions_clinically"></a><a name="section-7.3"></a><p></p>
<h2>Clinically Significant Drug Interactions</h2>
<p class="First">The benzodiazepines, including Ativan (lorazepam), produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics.</p>
<p>Concomitant use of clozapine and lorazepam may produce marked sedation, excessive <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.</p>
<p>Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately 50% when coadministered with valproate.</p>
<p>Concurrent administration of lorazepam with probenecid may results in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately 50% when coadministered with probenecid.</p>
<p>The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation.</p>
<p>Administration of theophylline or aminophylline may reduce the sedative effects of benzodiazepines, including lorazepam.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis and Mutagenesis</h2>
<p class="First">No evidence of carcinogenic potential emerged in rats during an 18-month study with Ativan (lorazepam). No studies regarding mutagenesis have been performed.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Reproductive studies in animals were performed in mice, rats, and two <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of rabbits. Occasional anomalies (reduction of tarsals, tibia, metatarsals, malrotated limbs, <span class="product-label-link" type="condition" conceptid="4218764" conceptname="Gastroschisis">gastroschisis</span>, malformed skull, and <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>) were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the concurrent control group, they have been reported to occur randomly in historical controls. At doses of 40 mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits which was not seen at lower doses.</p>
<p>The clinical significance of the above findings is not known. However, an increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Because the use of these drugs is rarely a matter of urgency, the use of lorazepam during this period should be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant, they should communicate with their physician about the desirability of discontinuing the drug.</p>
<p>In humans, blood levels obtained from umbilical cord blood indicate placental transfer of lorazepam and lorazepam glucuronide. Infants of mothers who ingested benzodiazepines for several weeks or more preceding delivery have been reported to have withdrawal symptoms during the postnatal period. Symptoms such as <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">hypoactivity</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, feeding problems, and impaired metabolic response to <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> stress have been reported in neonates born of mothers who have received benzodiazepines during the late phase of pregnancy or at delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Lorazepam has been detected in human breast milk; therefore, it should not be administered to breast-feeding women, unless the expected benefit to the woman outweighs the potential risk to the infant.</p>
<p>Sedation and inability to suckle have occurred in neonates of lactating mothers taking benzodiazepines. Infants of lactating mothers should be observed for pharmacological effects (including sedation and <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Ativan generally were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects; however, the incidence of sedation and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span> was observed to increase with age (see <span class="Bold"><a href="#Adverse">ADVERSE REACTIONS</a></span>).</p>
<p>Age does not appear to have a significant effect on lorazepam kinetics (see <span class="Bold"><a href="#Clinical">CLINICAL PHARMACOLOGY</a></span>).</p>
<p>Clinical circumstances, some of which may be more common in the elderly, such as hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, should be considered. Greater sensitivity (e.g., sedation) of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, and lower doses may be sufficient in these patients (see <span class="Bold"><a href="#Dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Most adverse reactions to benzodiazepines, including CNS effects and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, are dose dependent, with more severe effects occurring with high doses.</p>
<p>In a sample of about 3500 patients treated for <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, the most frequent adverse reaction to Ativan (lorazepam) was sedation (15.9%), followed by <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (6.9%), <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> (4.2%), and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span> (3.4%). The incidence of sedation and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span> increased with age.</p>
<p>Other adverse reactions to benzodiazepines, including lorazepam are <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, unmasking of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4249261" conceptname="Disinhibition">disinhibition</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>/attempt, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, eye-function/<span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span> (including <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>), <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>/<span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, change in libido, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, decreased orgasm; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, worsening of <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea</span>, worsening of obstructive pulmonary disease; <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, change in appetite, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, increase in bilirubin, increase in liver transaminases, increase in alkaline phosphatase; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, anaphylactic/oid reactions; dermatological symptoms, <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>; <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>; <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>; and autonomic manifestations.</p>
<p>Paradoxical reactions, including <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, excitation, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">rage</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span>/<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, sexual arousal, and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> may occur. Small decreases in blood pressure and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur but are usually not clinically significant, probably being related to the relief of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> produced by Ativan (lorazepam).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In postmarketing experience, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with lorazepam has occurred predominantly in combination with alcohol and/or other drugs. Therefore, in the management of overdosage, it should be borne in mind that multiple agents may have been taken.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Symptoms</h2>
<p class="First">Overdosage of benzodiazepines is usually manifested by varying degrees of central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> ranging from <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. In mild cases, symptoms include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, paradoxical reactions, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>. In more serious cases, and especially when other drugs or alcohol were ingested, symptoms may include <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, hypnotic state, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Management</h2>
<p class="First">General supportive and symptomatic measures are recommended; vital signs must be monitored and the patient closely observed. When there is a risk of <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is not recommended. Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients. Administration of activated charcoal may also limit drug absorption. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, though unlikely, usually may be controlled with norepinephrine bitartrate injection. Lorazepam is poorly dialyzable. Lorazepam glucuronide, the inactive metabolite, may be highly dialyzable.</p>
<p>The benzodiazepine antagonist flumazenil may be used in hospitalized patients as an adjunct to, not as a substitute for, proper management of benzodiazepine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. <span class="Bold">The prescriber should be aware of a risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span> The complete flumazenil package insert including <span class="Bold">CONTRAINDICATIONS</span>, <span class="Bold">WARNINGS</span>, and <span class="Bold">PRECAUTIONS</span> should be consulted prior to use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Dosage"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Ativan (lorazepam) is administered orally. For optimal results, dose, frequency of administration, and duration of therapy should be individualized according to patient response. To facilitate this, 0.5 mg, 1 mg, and 2 mg tablets are available.</p>
<p>The usual range is 2 to 6 mg/day given in divided doses, the largest dose being taken before bedtime, but the daily dosage may vary from 1 to 10 mg/day.</p>
<p>For <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, most patients require an initial dose of 2 to 3 mg/day given b.i.d. or t.i.d.</p>
<p>For <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> due to <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or transient situational stress, a single daily dose of 2 to 4 mg may be given, usually at bedtime.</p>
<p>For elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in divided doses is recommended, to be adjusted as needed and tolerated.</p>
<p>The dosage of Ativan (lorazepam) should be increased gradually when needed to help avoid adverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ativan<span class="Sup">®</span> (lorazepam) Tablets are available in the following dosage strengths:</p>
<p>0.5 mg, white, five-sided (shield shape) tablet with a raised "A" on one side and "BPI" and "63" impressed on reverse side.<br>  NDC 0187-0063-01 - Bottles of 100 tablets</p>
<p>1 mg, white, five-sided (shield shape) tablet with a raised "A" on one side and "BPI" and "64" impressed on scored reverse side.<br>  NDC 0187-0064-01 - Bottles of 100 tablets<br>  NDC 0187-0064-10 - Bottles of 1000 tablets</p>
<p>2 mg, white, five-sided (regular pentagon) tablet with a raised "A" and impressed "2" on one side and "BPI" and "65" impressed on scored reverse side.<br>  NDC 0187-0065-01 - Bottles of 100 tablets</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">BOTTLES:</span></p>
<p><span class="Bold">Keep tightly closed.</span></p>
<p><span class="Bold">Store at 25°C (77°F); excursions permitted to 15 - 30° (59 – 86°F) [see USP Controlled Room Temperature].</span></p>
<p><span class="Bold">Dispense in a tight container.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured by:<br>MEDA Manufacturing GmbH<br>Cologne, Germany D-51063</p>
<p>For:<br>Valeant Pharmaceuticals North America LLC<br>Bridgewater, NJ 08807 USA</p>
<p>Ativan<span class="Sup">®</span> is a registered trademark of Valeant International Bermuda.</p>
<p>Made in Germany</p>
<p>011625<br>Rev. 01/13</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 2.0 mg Bottle Label</h1>
<p class="First">NDC 0187-0065-01</p>
<p><span class="Bold">Ativan<span class="Sup">®</span></span><br>(lorazepam)</p>
<p><span class="Bold">2.0 mg</span></p>
<p><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">CIV</span><br>SEALED <br>FOR YOUR <br>PROTECTION</p>
<p>Rx only</p>
<p><span class="Bold">VALEANT<br>Pharmaceuticals North America LLC</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 2.0 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=89057c93-8155-4040-acec-64e877bd2b4c&amp;name=ativan-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 1.0 mg Bottle Label</h1>
<p class="First">NDC 0187-0064-01</p>
<p><span class="Bold">Ativan<span class="Sup">®</span></span><br>(lorazepam)</p>
<p><span class="Bold">1.0 mg</span></p>
<p><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">CIV</span><br>SEALED <br>FOR YOUR <br>PROTECTION</p>
<p>Rx only</p>
<p><span class="Bold">VALEANT<br>Pharmaceuticals North America LLC</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 1.0 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=89057c93-8155-4040-acec-64e877bd2b4c&amp;name=ativan-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.5 mg Bottle Label</h1>
<p class="First">NDC 0187-0063-01</p>
<p><span class="Bold">Ativan<span class="Sup">®</span></span><br>(lorazepam)</p>
<p><span class="Bold">0.5 mg</span></p>
<p><span class="Bold">100 Tablets</span></p>
<p><span class="Bold">CIV</span><br>SEALED <br>FOR YOUR <br>PROTECTION</p>
<p>Rx only</p>
<p><span class="Bold">VALEANT<br>Pharmaceuticals North America LLC</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=89057c93-8155-4040-acec-64e877bd2b4c&amp;name=ativan-08.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATIVAN 		
					</strong><br><span class="contentTableReg">lorazepam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0187-0063</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>lorazepam</strong> (lorazepam) </td>
<td class="formItem">lorazepam</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">PENTAGON (5 sided) (SHIELD SHAPE) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A;BPI;63</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0187-0063-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017794</td>
<td class="formItem">05/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATIVAN 		
					</strong><br><span class="contentTableReg">lorazepam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0187-0064</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>lorazepam</strong> (lorazepam) </td>
<td class="formItem">lorazepam</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">PENTAGON (5 sided) (SHIELD SHAPE) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A;BPI;64</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0187-0064-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0187-0064-10</td>
<td class="formItem">1000  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017794</td>
<td class="formItem">05/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ATIVAN 		
					</strong><br><span class="contentTableReg">lorazepam tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0187-0065</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>lorazepam</strong> (lorazepam) </td>
<td class="formItem">lorazepam</td>
<td class="formItem">2 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLACRILIN POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">PENTAGON (5 sided) (SHIELD SHAPE) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A;2;BPI;65</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0187-0065-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017794</td>
<td class="formItem">05/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Valeant Pharmaceuticals North America LLC
							(042230623)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">MEDA Manufacturing GmbH</td>
<td class="formItem"></td>
<td class="formItem">329238187</td>
<td class="formItem">MANUFACTURE(0187-0063, 0187-0064, 0187-0065)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>89057c93-8155-4040-acec-64e877bd2b4c</div>
<div>Set id: 89057c93-8155-4040-acec-64e877bd2b4c</div>
<div>Version: 1</div>
<div>Effective Time: 20130501</div>
</div>
</div> <div class="DistributorName">Valeant Pharmaceuticals North America LLC</div></p>
</body></html>
